Search results for "Progress"

showing 10 items of 1620 documents

Unusual giant chromophobe renal cancer totally managed with laparoscopic technique: Report of a case

2020

Highlights • We describe a case report of giant renal cell chromophobe carcinoma totally treated by laparoscopic surgery. • The size of renal lesion represents a critical point in surgical approach because to perform a laparoscopic radical nephrectomy can be challenging even for skilled surgeons in giant renal tumors. • A brief review of literature was performed to identify outcomes and potentially surgical advantages of laparoscopic approach for retroperitoenal liposarcoma. • The possibility of the laparoscopic approach derives from from the preoperative identification of adipose cleavage, from the absence of invasion of major vascular axes, from the absence of distant metastatic lesions.

medicine.medical_specialtymedicine.medical_treatmentChromophobe Renal Cell CarcinomaCase ReportChromophobe cellLesion03 medical and health sciences0302 clinical medicinemedicineAtypiaGiant renal massKidneybiologybusiness.industryCD117medicine.diseaseNephrectomyLaparoscopic nephrectomyChromophobe carcinomamedicine.anatomical_structureTumor progression030220 oncology & carcinogenesisbiology.proteinLaparoscopy030211 gastroenterology & hepatologySurgeryRadiologymedicine.symptombusinessInternational Journal of Surgery Case Reports
researchProduct

Chronic kidney disease and dyslipidaemia

2016

Chronic kidney disease (CKD) has to be considered as a high, or even very high risk cardiovascular risk condition, since it leads to an increase in cardiovascular mortality that continues to increase as the disease progresses. An early diagnosis of CKD is required, together with an adequate identification of the risk factors, in order to slow down its progression to more severe states, prevent complications, and to delay, whenever possible, the need for renal replacement therapy. Dyslipidaemia is a factor of the progression of CKD that increases the risk in developing atherosclerosis and its complications. Its proper control contributes to reducing the elevated cardiovascular morbidity and …

medicine.medical_specialtymedicine.medical_treatmentRenal functionDisease030204 cardiovascular system & hematologyurologic and male genital diseases03 medical and health sciences0302 clinical medicineRisk FactorsmedicineHumans030212 general & internal medicineRenal replacement therapyRenal Insufficiency ChronicIntensive care medicineDyslipidemiasGeneral Environmental ScienceCardiovascular mortalitybusiness.industryAnticholesteremic AgentsGeneral EngineeringCholesterol LDLmedicine.diseaseRenal Replacement TherapyCardiovascular DiseasesRenal transplantDisease ProgressionPhysical therapyGeneral Earth and Planetary SciencesHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessVery high riskDyslipidemiaKidney diseaseClínica e Investigación en Arteriosclerosis (English Edition)
researchProduct

Corneal opacity and copper levels of the Lewis syndrome after systemic chemotherapy

2020

Abstract Purpose To report a female patient of biclonal Lewis syndrome which consists of a trias: biclonal gammopathy of undetermined significance, paraproteinemic keratopathy in form of a brownish discoid opacification at the level of Descemet's membrane and hypercupremia. After several years there was a conversion to multiple myeloma. Systemic chemotherapy led to a complete remission of multiple myeloma and to a normalization of the copper level in the blood that lasted five years. The corneal opacification remained unchanged. Observations A currently 66-year-old woman suffered from biclonal Lewis syndrome. On both eyes there is a central discoid yellow-brownish discoloration in the Pre-D…

medicine.medical_specialtymedicine.medical_treatmentUnchanged corneal opacity after chemotherapyGastroenterology03 medical and health sciences0302 clinical medicinelcsh:OphthalmologyChemotherapy-induced normal level of copper in serumInternal medicineMedicineAffinity of IgG to copper in Lewis syndromeCopper levelsProgressive anemiaMultiple myelomaLewis syndromeHypercupremiaChemotherapyBiclonal gammopathybusiness.industrySystemic chemotherapyHypercupremiaCorneal opacitymedicine.diseaseOphthalmologylcsh:RE1-994030221 ophthalmology & optometrybusinessDiscoid brownish opacification of Descemet membrane030217 neurology & neurosurgeryAmerican Journal of Ophthalmology Case Reports
researchProduct

Urethral recurrence of transitional cell carcinoma in a female patient after cystectomy and orthotopic ileal neobladder.

2000

A 63-year-old woman presented elsewhere with a unifocal pT1, G3 transitional cell carcinoma at the bladder base in 1995. She underwent urethral sparing cystectomy and ileal neobladder. Intraoperative frozen section from the proximal urethra did not demonstrate tumor involvement. Final histological examination revealed pT1, pN2, G3 transitional cell carcinoma. Adjuvant chemotherapy was not given. In 1998 the patient had symptoms of obstructive voiding due to a 3 3 3 cm. solid mass at the neobladder-urethra anastomosis (see figure). After 6 cycles of methotrexate, vinblastine, doxorubicin and cisplatin and a transient tumor size reduction, the patient was referred to us for local tumor progre…

medicine.medical_specialtymedicine.medical_treatmentUrologyUrologyAnastomosisUrinary Diversionurologic and male genital diseasesCystectomyCystectomyUreterFatal OutcomemedicineHumansCarcinoma Transitional CellUrethral NeoplasmsUrinary bladderbusiness.industryUrinary diversionMiddle Agedmedicine.diseaseSurgeryTransitional cell carcinomaUrethramedicine.anatomical_structureUrinary Bladder NeoplasmsTumor progressionFemaleNeoplasm Recurrence LocalbusinessThe Journal of urology
researchProduct

The progression rate of aortic stenosis: key to tailoring the management and potential target for treatment

2021

: Aortic stenosis is the most frequent valvular disease to require intervention in the western world and has always been featured as a progressive disease. The rate of progression can be assessed by carefully performed Doppler echocardiography and can vary greatly between individuals with a profound impact on prognosis. Unfortunately, the determinants of disease progression had been insufficiently studied and remain challenging to define, particularly in the outpatient setting. Multiple factors have been proposed and tested, but at present, there are no proven therapies to slow the course of the stenotic process. Heart valve clinics may be particularly important to define the progression ra…

medicine.medical_specialtyprogression rateaortic stenosis degenerative progression rate valvulopathies030204 cardiovascular system & hematologyDoppler echocardiography03 medical and health sciences0302 clinical medicineValvular diseaseRisk FactorsmedicineHumansdegenerative030212 general & internal medicineHeart valveIntensive care medicinemedicine.diagnostic_testbusiness.industryDisease progressionaortic stenosisGeneral MedicineAortic Valve Stenosismedicine.diseasePrognosisvalvulopathiesEchocardiography DopplerStenosismedicine.anatomical_structureaortic stenosis; degenerative; progression rate; valvulopathiesAortic valve stenosisDisease ProgressionProgression rateCardiology and Cardiovascular MedicinebusinessProgressive disease
researchProduct

Vaccination with ENO1 DNA Prolongs Survival of Genetically Engineered Mice with Pancreatic Cancer

2013

Background & Aims Pancreatic ductal adenocarcinoma (PDA) is an aggressive tumor, and patients typically present with late-stage disease; rates of 5-year survival after pancreaticoduodenectomy are low. Antibodies against α-enolase (ENO1), a glycolytic enzyme, are detected in more than 60% of patients with PDA, and ENO1-specific T cells inhibit the growth of human pancreatic xenograft tumors in mice. We investigated whether an ENO1 DNA vaccine elicits antitumor immune responses and prolongs survival of mice that spontaneously develop autochthonous, lethal pancreatic carcinomas. Methods We injected and electroporated a plasmid encoding ENO1 (or a control plasmid) into Kras G12D /Cre (KC) mice …

medicine.medical_treatmentDNA Vaccine; Enolase; Parnceratic cancer; Transgeneic miceEnolasegenetically engineered miceceEnzyme-Linked Immunosorbent AssayTransgeneic miceDNA vaccination03 medical and health sciencesMice0302 clinical medicineImmune systemPancreatic cancerGenetic modelmedicineVaccines DNADNA VaccineAnimalsSurvival rate030304 developmental biology0303 health sciencesImmunity CellularHepatologybiologyENO.1; DNA Vaccine; genetically engineered miceceVaccinationGastroenterologyParnceratic cancerImmunotherapyNeoplasms Experimentalmedicine.diseaseImmunohistochemistryMice Mutant Strains3. Good healthPancreatic NeoplasmsSurvival RateSettore BIO/18 - GeneticaTumor progression030220 oncology & carcinogenesisPhosphopyruvate HydrataseImmunologybiology.proteinAntibodyENO.1Carcinoma Pancreatic Ductal
researchProduct

Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice.

2005

Type I interferons are associated with lupus. Genes that are regulated by IFN-alpha are upregulated in pediatric lupus patients. Gene deletion of the IFN-alpha/beta receptor in experimental lupus-like NZB mice results in reduced disease activity. Conversely, IFN-beta is a well-established treatment in multiple sclerosis, another autoimmune disease. For determining whether IFN-beta treatment is harmful or beneficial in lupus, MRL-Fas(lpr) mice were injected with this type I IFN. Treatment was initiated in MRL-Fas(lpr) mice with mild and advanced disease. IFN-beta was highly effective in prolonging survival and ameliorating the clinical (renal function, proteinuria, splenomegaly, and skin les…

medicine.medical_treatmentLupus nephritisImmunoglobulinsurologic and male genital diseasesmedicine.disease_causeKidneyAutoimmunityMiceImmune systemimmune system diseasesmedicineAnimalsLupus Erythematosus SystemicUreaskin and connective tissue diseasesSkinAutoimmune diseaseLupus erythematosusSystemic lupus erythematosusbusiness.industryGeneral MedicineImmunotherapymedicine.diseaseFlow CytometryLupus NephritisMice Mutant StrainsRecombinant ProteinsDisease Models AnimalProteinuriaCytokineNephrologyImmunoglobulin GImmunologyInterferon Type IDisease ProgressionbusinessCell DivisionJournal of the American Society of Nephrology : JASN
researchProduct

Proteomic profiling of vesicles released by 8701-bc cells

2008

8701-BC cells were shown to release “membrane vesicles” playing a role in tumor progression mechanisms. On the other hand, production of “exosomes”, smaller vesicles known to be involved in immune response activation, had not been revealed. The first goal of this study was to separate different vesicle populations from 8701-BC cell conditioned medium. To this aim, the medium was differentially centrifuged. Western analysis revealed that the 15,000xg pelletted fraction contains β1-integrin, which had been shown to be clustered in membrane vesicles shed by 8701-BC cells, but not Hsc70, a protein found in exosomes. On the contrary, Hsc70 is detectable while β1-integrin is not present in the fr…

membrane vesicles exosomes tumor progression proteomic analysis
researchProduct

ShRNA-mediated knock-down of CXCL8 inhibits tumor growth in colorectal liver metastasis.

2018

CXCL8 belongs to proinflammatory chemokines that are predominantly involved in neutrophil chemotaxis and degranulation. Several studies have suggested that secretion of CXCL8 from cancer cells have a profound effect on tumor microenvironment. In this study, in continuation to our previous work of understanding the global picture of invasion related genes in colorectal liver metastases, we clearly show an up-regulation of CXCL8 expression in the tumor cells at the invasion front as compared to the tumor cells in the inner parts of the tumor. Furthermore, ShRNA mediated down-regulation of CXCL8 resulted in inhibition of cell proliferation, viability and invasion in vitro and a near complete g…

musculoskeletal diseases0301 basic medicineAngiogenesisCell SurvivalBiophysicsDown-RegulationApoptosisBiologyBiochemistryProinflammatory cytokineMetastasis03 medical and health sciencesMice0302 clinical medicineCell Line TumormedicineAnimalsHumansNeoplasm InvasivenessAmino Acid SequenceRNA MessengerRNA Small InterferingMolecular BiologyProtein kinase BConserved SequenceCell ProliferationTumor microenvironmentInterleukin-8Liver NeoplasmsCell Biologymedicine.diseaseXenograft Model Antitumor AssaysUp-RegulationGene Expression Regulation NeoplasticVascular endothelial growth factor A030104 developmental biologyTumor progression030220 oncology & carcinogenesisGene Knockdown TechniquesCancer cellCancer researchColorectal NeoplasmsBiochemical and biophysical research communications
researchProduct

Manometric assessment of oesophageal involvement in progressive systemic sclerosis, morphoea and Raynaud's disease.

1982

SUMMARY Oesophageal function was studied by radiography and manometry in fifty-one patients with progressive systemic sclerosis (PSS), fourteen patients with morphoea, twelve patients with Raynaud's disease and twenty-one normal subjects. Upper oesophageal sphincter pressure was not affected. Peristaltic contractions of the upper third of the oesophagus were significantly decreased in PSS and morphoea, but the lower two-thirds were affected only in PSS. Lower oesophageal sphincter pressure was significantly decreased in PSS but was normal in morphoea and Raynaud's disease. There was a significant correlation between oesophageal dysfunction and the duration of PSS. Manometry was better than …

musculoskeletal diseasesAdultMalemedicine.medical_specialtyTime FactorsOesophageal manometryAdolescentManometryRadiographyDermatologySkin DiseasesScleroderma LocalizedEsophagusstomatognathic systemLower oesophageal sphincter pressurePressureMedicineUpper oesophageal sphincter pressureHumansAgedScleroderma Systemicbusiness.industryProgressive systemic sclerosisRaynaud DiseaseMiddle Agedmedicine.diseaseeye diseasesRadiographystomatognathic diseasesRaynaud's diseaseFemaleUpper thirdRadiologyOesophageal functionbusinessThe British journal of dermatology
researchProduct